Amicus Therapeutics Announces Second Quarter 2008 Results Release Date

CRANBURY, N.J., July 31 /PRNewswire-FirstCall/ -- Amicus Therapeutics
(Nasdaq: FOLD), a biopharmaceutical company developing small molecule,
orally-administered pharmacological chaperones for the treatment of human
genetic diseases, will announce second quarter 2008 financial results after
the regular close of markets on Thursday, August 7, 2008. The results
announcement will be followed by a live conference call and webcast that
afternoon at 5 p.m. EDT.
Interested participants and investors may access the conference call at 5
p.m. EDT by dialing 877-340-7913 (U.S./Canada) or 719-325-4847
(international). A telephonic replay of the call will be available for seven
days beginning at 8 p.m. EDT. Access numbers for this replay are 888-203-1112
(U.S./Canada) and 719-457-0820 (international); participant code 8324472.
An audio webcast can also be accessed via the investor section of the
Amicus Therapeutics Web site at http://www.amicustherapeutics.com under
Investors: Events and Presentations. Web participants are encouraged to go to
the Web site 15 minutes prior to the start of the call to register, download
and install any necessary software. After the live webcast, a webcast replay
will remain available in the Investors section of the Amicus Therapeutics Web
site for 30 days.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral
therapeutics known as pharmacological chaperones for the treatment of a range
of human genetic diseases. Pharmacological chaperone technology involves the
use of small molecules that selectively bind to and stabilize proteins in
cells, leading to improved protein folding and trafficking, and increased
activity. Amicus is initially targeting lysosomal storage disorders, which are
severe, chronic genetic diseases with unmet medical needs. Amicus has
completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease
and is conducting Phase 2 clinical trials of Plicera for the treatment of
Gaucher disease and AT2220 for the treatment of Pompe disease.
FOLD-G
SOURCE Amicus Therapeutics

Investors, John Quirk, +1-212-601-8296, or Cory Tromblee, +1-617-897-8294,
both of Porter Novelli Life Sciences, for Amicus Therapeutics